{"id":3166,"date":"2026-10-14T15:31:44","date_gmt":"2026-10-14T10:01:44","guid":{"rendered":"https:\/\/www.biospherecro.com\/?p=3166"},"modified":"2026-10-14T17:44:08","modified_gmt":"2026-10-14T12:14:08","slug":"sugam-submission-the-complete-2026-guide-to-cdscos-online-drug-application-portal","status":"publish","type":"post","link":"https:\/\/www.biospherecro.com\/sugam-submission-the-complete-2026-guide-to-cdscos-online-drug-application-portal\/","title":{"rendered":"Sugam Submission: The Complete 2026 Guide to CDSCO&#8217;s Online Drug Application Portal"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"3166\" class=\"elementor elementor-3166\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b93e90a elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"b93e90a\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3098bc6\" data-id=\"3098bc6\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2236835 elementor-widget elementor-widget-text-editor\" data-id=\"2236835\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>If you are a pharmaceutical company, a biotech sponsor, a <a href=\"https:\/\/www.biospherecro.com\/\">clinical research organisation<\/a>, or a medical device manufacturer planning to register or conduct clinical activities in India, there is one digital system you need to understand before anything else: the SUGAM portal.<\/p><p>India is the world&#8217;s third-largest pharmaceutical industry by volume, with a rapidly maturing regulatory infrastructure under the Central Drugs Standard Control Organisation (CDSCO). All drug registrations, <a href=\"https:\/\/www.biospherecro.com\/\">clinical trial services<\/a> approvals, import licences, and medical device registrations now flow through a single electronic system &#8211; SUGAM &#8211; and getting your submission right on that portal is the difference between a smooth approval timeline and months of avoidable delay.<\/p><p>This guide covers everything sponsors need to know about SUGAM submission in 2026: what the portal is, what it handles, how to navigate it, what documentation is required, and the most common mistakes that send applications back.<\/p><h2><strong>Quick Answer<\/strong><\/h2><p>The SUGAM portal is CDSCO&#8217;s official online platform for submitting, tracking, and managing regulatory applications in India &#8211; including new drug registrations, <a href=\"https:\/\/www.biospherecro.com\/\">clinical trial services<\/a> permissions, medical device approvals, and import licences. Applications must be submitted in CTD format (eCTD recommended for new drugs), with India-specific Module 1 documentation tailored to CDSCO requirements. The NDCT Amendment Rules 2026 update several requirements relevant to clinical trial sponsors.<\/p><h2><strong>What Is the SUGAM Portal?<\/strong><\/h2><p>SUGAM &#8211; an acronym for Sugam (easy) &#8211; is CDSCO&#8217;s integrated e-governance system for electronic submission and tracking of regulatory applications. Before SUGAM, applicants physically submitted paper dossiers to CDSCO offices. The transition to an electronic, centralised system has significantly improved transparency, tracking, and communication between sponsors and regulators.<\/p><p>The portal handles:<\/p><ul><li>New drug applications (NDAs) for drugs not previously approved in India<\/li><li>Import registration certificates for foreign drugs<\/li><li><a href=\"https:\/\/www.biospherecro.com\/\">Clinical trial services<\/a> applications &#8211; CT-01, CT-04, and CT-06 forms under NDCT Rules 2019<\/li><li>Abbreviated New Drug Applications (ANDAs) for generic drugs<\/li><li>Medical device registration (Classes A, B, C, and D)<\/li><li>Cosmetics manufacturing and import approvals<\/li><li>Licence renewals and variation applications<\/li><li>Export certificates and No Objection Certificates (NOCs)<\/li><\/ul><p>For any company needing a licence or approval from CDSCO, SUGAM is where the regulatory journey in India begins and where it is tracked throughout.<\/p><h2><strong>The Regulatory Framework: NDCT Rules 2019 and the 2026 Amendment<\/strong><\/h2><p>The New Drugs and Clinical Trials (NDCT) Rules, 2019 &#8211; issued under India&#8217;s Drugs and Cosmetics Act, 1940 &#8211; is the foundational framework governing clinical trial permissions, new drug approvals, Ethics Committee registrations, and bioavailability\/bioequivalence (BA\/BE) studies in India.<\/p><p>In January 2026, the Ministry of Health and Family Welfare notified the New Drugs and Clinical Trials (Amendment) Rules, 2026 (G.S.R. 46(E), dated 20 January 2026). Sponsors running <a href=\"https:\/\/www.biospherecro.com\/\">clinical trial services<\/a> in India should review this amendment carefully &#8211; it introduces updated documentation requirements and procedural clarifications that affect SUGAM submissions.<\/p><p>The DCGI (Drugs Controller General of India), who heads CDSCO, is the Central Licensing Authority under the NDCT Rules and the officer who grants or refuses clinical trial permission and new drug approval. All correspondence with CDSCO flows through the SUGAM portal.<\/p><h2><strong>SUGAM Application Types and Timelines<\/strong><\/h2><p><strong>Key Application Types, Forms, and Review Timelines<\/strong><\/p><table style=\"width: 100%; border-collapse: collapse; font-family: Arial, sans-serif; font-size: 14px; color: #111;\"><thead><tr style=\"background-color: #205b85; color: #ffffff;\"><th style=\"border: 1px solid #333; padding: 4px 8px; text-align: left;\">Application Type<\/th><th style=\"border: 1px solid #333; padding: 4px 8px; text-align: left;\">Form<\/th><th style=\"border: 1px solid #333; padding: 4px 8px; text-align: left;\">Standard Timeline<\/th><th style=\"border: 1px solid #333; padding: 4px 8px; text-align: left;\">Portal<\/th><\/tr><\/thead><tbody><tr style=\"background-color: #ffffff;\"><td style=\"border: 1px solid #333; padding: 4px 8px;\">New Drug (import)<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">CT-04 \/ Form 45<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">12 months<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">SUGAM<\/td><\/tr><tr style=\"background-color: #eaf0f8;\"><td style=\"border: 1px solid #333; padding: 4px 8px;\">Clinical Trial Permission<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">CT-01 \/ CT-06<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">90 working days<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">SUGAM<\/td><\/tr><tr style=\"background-color: #ffffff;\"><td style=\"border: 1px solid #333; padding: 4px 8px;\">Generic Drug (ANDA)<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">Form 10 \/ 12<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">9\u201312 months<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">SUGAM<\/td><\/tr><tr style=\"background-color: #eaf0f8;\"><td style=\"border: 1px solid #333; padding: 4px 8px;\">Medical Device (Class C\/D)<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">MD-14 \/ MD-41<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">8\u201316 weeks<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">SUGAM<\/td><\/tr><tr style=\"background-color: #ffffff;\"><td style=\"border: 1px solid #333; padding: 4px 8px;\">Biological Product<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">Form 44 \/ Form 12C<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">12 months<\/td><td style=\"border: 1px solid #333; padding: 4px 8px;\">SUGAM<\/td><\/tr><\/tbody><\/table><p>\u00a0<\/p><h2><strong>Step-by-Step Guide to SUGAM Submission<\/strong><\/h2><h3><strong>Step 1: Register on the SUGAM Portal<\/strong><\/h3><p>Every sponsor, manufacturer, or authorised agent must create an account on the SUGAM portal (sugam.pharma.gov.in) before any application can be submitted. The registration process requires:<\/p><ul><li>A valid business email address and Indian mobile number for OTP verification<\/li><li>Company registration documents (Certificate of Incorporation or equivalent)<\/li><li>For foreign companies: appointment letter for the Authorised Indian Agent, who must hold a valid wholesale drug licence in India<\/li><li>Digital Signature Certificate (DSC) for authorised signatories<\/li><\/ul><p>Account verification typically takes 3 to 5 working days after document submission.<\/p><h3><strong>Step 2: Prepare Your CTD Dossier<\/strong><\/h3><p>All new drug applications and <a href=\"https:\/\/www.biospherecro.com\/\">clinical trial services<\/a> applications submitted through SUGAM must be organised in Common Technical Document (CTD) format. For new drug applications, eCTD format is recommended and increasingly expected. The five CTD modules are:<\/p><ul><li><strong>Module 1<\/strong> &#8211; India-specific administrative and regional information (this is where most SUGAM-specific errors occur)<\/li><li><strong>Module 2<\/strong> &#8211; Summaries and overviews (Quality Overall Summary, Non-Clinical Overview, Clinical Overview, Clinical Summary)<\/li><li><strong>Module 3<\/strong> &#8211; Quality \/ Chemistry, Manufacturing, and Controls (CMC)<\/li><li><strong>Module 4<\/strong> &#8211; Non-clinical study reports<\/li><li><strong>Module 5<\/strong> &#8211; Clinical study reports (including all <a href=\"https:\/\/www.biospherecro.com\/data-management\/\">clinical trial data management<\/a> outputs)<\/li><\/ul><p>India-specific Module 1 is the section most frequently incomplete in SUGAM submissions. Key required items include:<\/p><ul><li>Covering letter and Form 44 (or the applicable form for the application type)<\/li><li>Proof of approval in the country of origin (for imported drugs), with translations if not in English<\/li><li>GMP certificates for all manufacturing sites, valid at the time of submission<\/li><li>Site master file or abbreviated site master file for manufacturing sites<\/li><li>Prescribing information in the format approved in the reference country<\/li><li>Declaration by the applicant regarding bioequivalence and safety<\/li><\/ul><h3><strong>Step 3: Address Local Clinical Data Requirements<\/strong><\/h3><p>CDSCO may require India-specific clinical bridging data for new drugs not previously approved in the major ICH reference countries (US, EU, Japan, UK, Canada, Australia). The requirement is evaluated on a product-by-product basis and may involve:<\/p><ul><li><a href=\"https:\/\/www.biospherecro.com\/\">Clinical trial services <\/a>&#8211; Phase III bridging studies in Indian patients<\/li><li>Phase I pharmacokinetic studies in Indian subjects<\/li><li>Post-marketing safety data in Indian patients for drugs already approved elsewhere<\/li><\/ul><p>Sponsors should seek expert regulatory advice early &#8211; ideally at pre-SUGAM submission consultation, if available to determine whether local clinical data will be required for their specific product.<\/p><h3><strong>Step 4: Submit Through SUGAM and Pay Fees<\/strong><\/h3><p>Once the dossier is prepared and the account is verified, the application is uploaded through SUGAM and the applicable fee is paid electronically. CDSCO fee schedules are published on the SUGAM portal and vary by application type, drug category, and whether the application is from a domestic or foreign manufacturer.<\/p><p>After submission, SUGAM provides a reference number that enables real-time tracking of the application status, communication of CDSCO queries, and management of the entire review lifecycle digitally.<\/p><h3><strong>Step 5: Respond to CDSCO Queries<\/strong><\/h3><p>CDSCO reviewers issue written queries through the SUGAM portal during the review. These must be responded to within the timeframe specified in the query notification. Each query response must be uploaded to SUGAM as a structured response document.<\/p><p>The quality of query responses is a critical determinant of approval timeline. A precise, complete, and well-structured response drafted by experienced <a href=\"https:\/\/www.biospherecro.com\/medical-writing\/\">regulatory medical writing<\/a> specialists can resolve a query in one cycle. A vague or incomplete response extends the review.<\/p><h2><strong>Common SUGAM Submission Errors<\/strong><\/h2><p><strong>Incorrect application form selection: <\/strong>CT-01 (new clinical trial), CT-04 (import of investigational product for trial), and CT-06 (BA\/BE study) serve different purposes. Using the wrong form is a frequent and easily avoidable error.<\/p><p><strong>Incomplete Module 1 India documentation: <\/strong>Missing GMP certificates, absent proof of origin country approval, or outdated prescribing information are the most frequently cited completeness deficiencies in CDSCO review feedback.<\/p><p><strong>Absent or insufficient local bridging data: <\/strong>Where CDSCO requires local clinical data, submitting without it &#8211; or with inadequate data &#8211; results in rejection or a request for a bridging study that adds months to the timeline.<\/p><p><strong>Dossier formatting non-compliance: <\/strong>Submissions not organised in CTD format, or with files submitted in non-PDF formats, or without the structured CTD table of contents, generate immediate technical rejection.<\/p><p><strong>Expired GMP certificates at time of review: <\/strong>GMP certificates that were valid at submission may expire during the review period. Sponsors should track certificate expiry dates and upload renewals proactively through SUGAM.<\/p><h2><strong>How SUGAM Fits Into a Global Regulatory Strategy<\/strong><\/h2><p>For sponsors conducting multi-country <a href=\"https:\/\/www.biospherecro.com\/\">clinical trial services<\/a> or pursuing simultaneous marketing authorisations, SUGAM submission in India must be planned alongside submissions to the FDA, EMA, MHRA, TGA, and other authorities.<\/p><p>India is an increasingly significant target market and a high-value clinical trial location &#8211; particularly for rare diseases, oncology, infectious disease, and CNS conditions where India offers large patient populations, lower study costs, and experienced site networks. Experienced <a href=\"https:\/\/www.biospherecro.com\/\">clinical research organisations<\/a> operating in India combine SUGAM expertise with global CTD dossier preparation capability to ensure India timelines align with global submission plans.<\/p><p>The global regulatory medical writing approach &#8211; building Module 2 summaries and overviews that work across FDA, EMA, and CDSCO, with authority-specific Module 1 adaptations &#8211; is the most efficient path for sponsors pursuing simultaneous global approvals.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6f28fed elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"6f28fed\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-9716e6c\" data-id=\"9716e6c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-96b539f elementor-widget elementor-widget-heading\" data-id=\"96b539f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Frequently Asked Questions<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6536ed5 elementor-widget elementor-widget-eael-adv-accordion\" data-id=\"6536ed5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"eael-adv-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t            <div class=\"eael-adv-accordion\" id=\"eael-adv-accordion-6536ed5\" data-scroll-on-click=\"no\" data-scroll-speed=\"300\" data-accordion-id=\"6536ed5\" data-accordion-type=\"accordion\" data-toogle-speed=\"300\">\n            <div class=\"eael-accordion-list\">\n\t\t\t\t\t<div id=\"1-what-is-the-sugam-portal\" class=\"elementor-tab-title eael-accordion-header active-default\" tabindex=\"0\" data-tab=\"1\" aria-controls=\"elementor-tab-content-1061\"><span class=\"eael-advanced-accordion-icon-closed\"><\/span><span class=\"eael-advanced-accordion-icon-opened\"><\/span><span class=\"eael-accordion-tab-title\">1. What is the SUGAM portal?<\/span><i aria-hidden=\"true\" class=\"fa-toggle fas fa-angle-right\"><\/i><\/div><div id=\"elementor-tab-content-1061\" class=\"eael-accordion-content clearfix active-default\" data-tab=\"1\" aria-labelledby=\"1-what-is-the-sugam-portal\"><p>SUGAM is CDSCO&#8217;s official online platform for electronic submission, tracking, and management of all Indian pharmaceutical and medical device regulatory applications \u2014 new drug registrations, clinical trial permissions, import licences, and more.<\/p><\/div>\n\t\t\t\t\t<\/div><div class=\"eael-accordion-list\">\n\t\t\t\t\t<div id=\"2-what-ctd-modules-are-most-commonly-incomplete-in-sugam-submissions\" class=\"elementor-tab-title eael-accordion-header\" tabindex=\"0\" data-tab=\"2\" aria-controls=\"elementor-tab-content-1062\"><span class=\"eael-accordion-tab-title\">2. What CTD modules are most commonly incomplete in SUGAM submissions?<\/span><i aria-hidden=\"true\" class=\"fa-toggle fas fa-angle-right\"><\/i><\/div><div id=\"elementor-tab-content-1062\" class=\"eael-accordion-content clearfix\" data-tab=\"2\" aria-labelledby=\"2-what-ctd-modules-are-most-commonly-incomplete-in-sugam-submissions\"><p>India-specific Module 1 documentation &#8211; covering letters, Form 44, GMP certificates, proof of origin country approval, and prescribing information &#8211; is the most frequently incomplete section in SUGAM submissions.<\/p><\/div>\n\t\t\t\t\t<\/div><div class=\"eael-accordion-list\">\n\t\t\t\t\t<div id=\"3-does-india-require-local-clinical-trial-data-for-all-new-drugs\" class=\"elementor-tab-title eael-accordion-header\" tabindex=\"0\" data-tab=\"3\" aria-controls=\"elementor-tab-content-1063\"><span class=\"eael-accordion-tab-title\">3. Does India require local clinical trial data for all new drugs?<\/span><i aria-hidden=\"true\" class=\"fa-toggle fas fa-angle-right\"><\/i><\/div><div id=\"elementor-tab-content-1063\" class=\"eael-accordion-content clearfix\" data-tab=\"3\" aria-labelledby=\"3-does-india-require-local-clinical-trial-data-for-all-new-drugs\"><p>Not for all &#8211; it depends on prior approval status in ICH reference countries, product type, and indication. Sponsors should obtain regulatory advice early to determine whether local bridging data will be required for their specific product.<\/p><\/div>\n\t\t\t\t\t<\/div><div class=\"eael-accordion-list\">\n\t\t\t\t\t<div id=\"4-what-are-the-ndct-amendment-rules-2026\" class=\"elementor-tab-title eael-accordion-header\" tabindex=\"0\" data-tab=\"4\" aria-controls=\"elementor-tab-content-1064\"><span class=\"eael-accordion-tab-title\">4. What are the NDCT Amendment Rules 2026?<\/span><i aria-hidden=\"true\" class=\"fa-toggle fas fa-angle-right\"><\/i><\/div><div id=\"elementor-tab-content-1064\" class=\"eael-accordion-content clearfix\" data-tab=\"4\" aria-labelledby=\"4-what-are-the-ndct-amendment-rules-2026\"><p>The New Drugs and Clinical Trials (Amendment) Rules, 2026 (G.S.R. 46(E), 20 January 2026) update several procedural requirements under the original NDCT Rules 2019. Clinical trial sponsors operating in India should review this amendment and its implications for pending and planned SUGAM submissions.<\/p><\/div>\n\t\t\t\t\t<\/div><div class=\"eael-accordion-list\">\n\t\t\t\t\t<div id=\"5-how-long-does-cdsco-review-take\" class=\"elementor-tab-title eael-accordion-header\" tabindex=\"0\" data-tab=\"5\" aria-controls=\"elementor-tab-content-1065\"><span class=\"eael-accordion-tab-title\">5. How long does CDSCO review take?<\/span><i aria-hidden=\"true\" class=\"fa-toggle fas fa-angle-right\"><\/i><\/div><div id=\"elementor-tab-content-1065\" class=\"eael-accordion-content clearfix\" data-tab=\"5\" aria-labelledby=\"5-how-long-does-cdsco-review-take\"><p>Clinical trial permission has a statutory 90-working-day review under NDCT Rules. New drug import registrations take approximately 12 months. Generic drug (ANDA) applications take 9 to 12 months. Timelines may extend if CDSCO issues queries that require a response before the review can progress.<\/p><\/div>\n\t\t\t\t\t<\/div><\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-27a2f1c elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-column-slider-no wpr-equal-height-no\" data-id=\"27a2f1c\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fe755f8\" data-id=\"fe755f8\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1965af7 elementor-widget elementor-widget-text-editor\" data-id=\"1965af7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong>Conclusion<\/strong><\/h3><p>The SUGAM portal has meaningfully modernised India&#8217;s pharmaceutical regulatory landscape, replacing a paper-based system with a structured, transparent electronic submission process. For sponsors, this creates both opportunity and responsibility: the process is clearer, but the documentation standards are increasingly rigorous.<\/p><p>Success with SUGAM submission in 2026 requires a thorough understanding of CDSCO&#8217;s documentation requirements, a CTD-formatted dossier that meets both global and India-specific standards, proactive management of local clinical data requirements, and experienced <a href=\"https:\/\/www.biospherecro.com\/medical-writing\/\">regulatory medical writing<\/a> support that understands both the SUGAM portal&#8217;s mechanics and CDSCO&#8217;s regulatory expectations.<\/p><p>Whether you are registering an innovative drug, managing <a href=\"https:\/\/www.biospherecro.com\/clinical-trial-services\/\">clinical trial services<\/a> in India, or coordinating a global submission strategy that includes India, our specialist <a href=\"https:\/\/www.biospherecro.com\/medical-writing\/\">regulatory medical writing<\/a> and <a href=\"https:\/\/www.biospherecro.com\/regulatory-affairs\/\">regulatory affairs<\/a> team provides end-to-end SUGAM submission support.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>If you are a pharmaceutical company, a biotech sponsor, a clinical research organisation, or a medical device manufacturer planning to register or conduct clinical activities in India, there is one digital system you need to understand before anything else: the SUGAM portal. India is the world&#8217;s third-largest pharmaceutical industry by volume, with a rapidly maturing regulatory infrastructure under the Central Drugs Standard Control Organisation (CDSCO). All drug registrations, clinical trial services approvals, import licences, and medical device registrations now flow through a single electronic system &#8211; SUGAM &#8211; and getting your submission right on that portal is the difference between a smooth approval timeline and months of avoidable delay. This guide covers everything sponsors need to know about SUGAM submission in 2026: what the portal is, what it handles, how to navigate it, what documentation is required, and the most common mistakes that send applications back. Quick Answer The SUGAM portal is CDSCO&#8217;s official online platform for submitting, tracking, and managing regulatory applications in India &#8211; including new drug registrations, clinical trial services permissions, medical device approvals, and import licences. Applications must be submitted in CTD format (eCTD recommended for new drugs), with India-specific Module 1 documentation tailored to CDSCO requirements. The NDCT Amendment Rules 2026 update several requirements relevant to clinical trial sponsors. What Is the SUGAM Portal? SUGAM &#8211; an acronym for Sugam (easy) &#8211; is CDSCO&#8217;s integrated e-governance system for electronic submission and tracking of regulatory applications. Before SUGAM, applicants physically submitted paper dossiers to CDSCO offices. The transition to an electronic, centralised system has significantly improved transparency, tracking, and communication between sponsors and regulators. The portal handles: New drug applications (NDAs) for drugs not previously approved in India Import registration certificates for foreign drugs Clinical trial services applications &#8211; CT-01, CT-04, and CT-06 forms under NDCT Rules 2019 Abbreviated New Drug Applications (ANDAs) for generic drugs Medical device registration (Classes A, B, C, and D) Cosmetics manufacturing and import approvals Licence renewals and variation applications Export certificates and No Objection Certificates (NOCs) For any company needing a licence or approval from CDSCO, SUGAM is where the regulatory journey in India begins and where it is tracked throughout. The Regulatory Framework: NDCT Rules 2019 and the 2026 Amendment The New Drugs and Clinical Trials (NDCT) Rules, 2019 &#8211; issued under India&#8217;s Drugs and Cosmetics Act, 1940 &#8211; is the foundational framework governing clinical trial permissions, new drug approvals, Ethics Committee registrations, and bioavailability\/bioequivalence (BA\/BE) studies in India. In January 2026, the Ministry of Health and Family Welfare notified the New Drugs and Clinical Trials (Amendment) Rules, 2026 (G.S.R. 46(E), dated 20 January 2026). Sponsors running clinical trial services in India should review this amendment carefully &#8211; it introduces updated documentation requirements and procedural clarifications that affect SUGAM submissions. The DCGI (Drugs Controller General of India), who heads CDSCO, is the Central Licensing Authority under the NDCT Rules and the officer who grants or refuses clinical trial permission and new drug approval. All correspondence with CDSCO flows through the SUGAM portal. SUGAM Application Types and Timelines Key Application Types, Forms, and Review Timelines Application Type Form Standard Timeline Portal New Drug (import) CT-04 \/ Form 45 12 months SUGAM Clinical Trial Permission CT-01 \/ CT-06 90 working days SUGAM Generic Drug (ANDA) Form 10 \/ 12 9\u201312 months SUGAM Medical Device (Class C\/D) MD-14 \/ MD-41 8\u201316 weeks SUGAM Biological Product Form 44 \/ Form 12C 12 months SUGAM \u00a0 Step-by-Step Guide to SUGAM Submission Step 1: Register on the SUGAM Portal Every sponsor, manufacturer, or authorised agent must create an account on the SUGAM portal (sugam.pharma.gov.in) before any application can be submitted. The registration process requires: A valid business email address and Indian mobile number for OTP verification Company registration documents (Certificate of Incorporation or equivalent) For foreign companies: appointment letter for the Authorised Indian Agent, who must hold a valid wholesale drug licence in India Digital Signature Certificate (DSC) for authorised signatories Account verification typically takes 3 to 5 working days after document submission. Step 2: Prepare Your CTD Dossier All new drug applications and clinical trial services applications submitted through SUGAM must be organised in Common Technical Document (CTD) format. For new drug applications, eCTD format is recommended and increasingly expected. The five CTD modules are: Module 1 &#8211; India-specific administrative and regional information (this is where most SUGAM-specific errors occur) Module 2 &#8211; Summaries and overviews (Quality Overall Summary, Non-Clinical Overview, Clinical Overview, Clinical Summary) Module 3 &#8211; Quality \/ Chemistry, Manufacturing, and Controls (CMC) Module 4 &#8211; Non-clinical study reports Module 5 &#8211; Clinical study reports (including all clinical trial data management outputs) India-specific Module 1 is the section most frequently incomplete in SUGAM submissions. Key required items include: Covering letter and Form 44 (or the applicable form for the application type) Proof of approval in the country of origin (for imported drugs), with translations if not in English GMP certificates for all manufacturing sites, valid at the time of submission Site master file or abbreviated site master file for manufacturing sites Prescribing information in the format approved in the reference country Declaration by the applicant regarding bioequivalence and safety Step 3: Address Local Clinical Data Requirements CDSCO may require India-specific clinical bridging data for new drugs not previously approved in the major ICH reference countries (US, EU, Japan, UK, Canada, Australia). The requirement is evaluated on a product-by-product basis and may involve: Clinical trial services &#8211; Phase III bridging studies in Indian patients Phase I pharmacokinetic studies in Indian subjects Post-marketing safety data in Indian patients for drugs already approved elsewhere Sponsors should seek expert regulatory advice early &#8211; ideally at pre-SUGAM submission consultation, if available to determine whether local clinical data will be required for their specific product. Step 4: Submit Through SUGAM and Pay Fees Once the dossier is prepared and the account is verified, the application is uploaded through SUGAM and the applicable fee is paid electronically. CDSCO fee schedules are published on the SUGAM portal and vary<\/p>\n","protected":false},"author":12,"featured_media":3167,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[199],"tags":[],"class_list":["post-3166","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-application-portal"],"_links":{"self":[{"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/posts\/3166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/comments?post=3166"}],"version-history":[{"count":20,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/posts\/3166\/revisions"}],"predecessor-version":[{"id":3189,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/posts\/3166\/revisions\/3189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/media\/3167"}],"wp:attachment":[{"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/media?parent=3166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/categories?post=3166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biospherecro.com\/wp-json\/wp\/v2\/tags?post=3166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}